KR101725469B1 - 인돌리논 유도체의 현탁 제형을 포함하는 캡슐 약제학적 투여 형태 - Google Patents

인돌리논 유도체의 현탁 제형을 포함하는 캡슐 약제학적 투여 형태 Download PDF

Info

Publication number
KR101725469B1
KR101725469B1 KR1020107027317A KR20107027317A KR101725469B1 KR 101725469 B1 KR101725469 B1 KR 101725469B1 KR 1020107027317 A KR1020107027317 A KR 1020107027317A KR 20107027317 A KR20107027317 A KR 20107027317A KR 101725469 B1 KR101725469 B1 KR 101725469B1
Authority
KR
South Korea
Prior art keywords
capsule
formulation
active substance
delete delete
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107027317A
Other languages
English (en)
Korean (ko)
Other versions
KR20110017872A (ko
Inventor
로만 메쎄르슈미트
루돌프 빈더
토마스 복
베르너 브록스
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101725469(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20110017872A publication Critical patent/KR20110017872A/ko
Application granted granted Critical
Publication of KR101725469B1 publication Critical patent/KR101725469B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107027317A 2008-06-06 2009-06-04 인돌리논 유도체의 현탁 제형을 포함하는 캡슐 약제학적 투여 형태 Active KR101725469B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08157748.8 2008-06-06
EP08157748 2008-06-06
PCT/EP2009/056878 WO2009147212A1 (en) 2008-06-06 2009-06-04 Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177004310A Division KR20170020557A (ko) 2008-06-06 2009-06-04 인돌리논 유도체의 현탁 제형을 포함하는 캡슐 약제학적 투여 형태

Publications (2)

Publication Number Publication Date
KR20110017872A KR20110017872A (ko) 2011-02-22
KR101725469B1 true KR101725469B1 (ko) 2017-04-11

Family

ID=40911908

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107027317A Active KR101725469B1 (ko) 2008-06-06 2009-06-04 인돌리논 유도체의 현탁 제형을 포함하는 캡슐 약제학적 투여 형태
KR1020177004310A Withdrawn KR20170020557A (ko) 2008-06-06 2009-06-04 인돌리논 유도체의 현탁 제형을 포함하는 캡슐 약제학적 투여 형태

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177004310A Withdrawn KR20170020557A (ko) 2008-06-06 2009-06-04 인돌리논 유도체의 현탁 제형을 포함하는 캡슐 약제학적 투여 형태

Country Status (35)

Country Link
US (4) US20110301177A1 (enExample)
EP (1) EP2299987B1 (enExample)
JP (2) JP5661031B2 (enExample)
KR (2) KR101725469B1 (enExample)
CN (2) CN102056598B (enExample)
AR (1) AR072059A1 (enExample)
AU (1) AU2009254548B2 (enExample)
BR (1) BRPI0913434B8 (enExample)
CA (1) CA2726267C (enExample)
CL (1) CL2010001279A1 (enExample)
CO (1) CO6280467A2 (enExample)
CY (1) CY1120533T1 (enExample)
DK (1) DK2299987T3 (enExample)
EA (1) EA029996B1 (enExample)
EC (1) ECSP10010660A (enExample)
ES (1) ES2669469T3 (enExample)
HR (1) HRP20180709T1 (enExample)
HU (1) HUE039187T2 (enExample)
IL (1) IL208954A (enExample)
LT (1) LT2299987T (enExample)
MA (1) MA32385B1 (enExample)
MX (2) MX359229B (enExample)
MY (1) MY158930A (enExample)
NO (1) NO2299987T3 (enExample)
NZ (1) NZ603162A (enExample)
PE (1) PE20100254A1 (enExample)
PL (1) PL2299987T3 (enExample)
PT (1) PT2299987T (enExample)
RS (1) RS57142B1 (enExample)
SI (1) SI2299987T1 (enExample)
TW (1) TW201002691A (enExample)
UA (1) UA104590C2 (enExample)
UY (1) UY31879A (enExample)
WO (1) WO2009147212A1 (enExample)
ZA (1) ZA201007636B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
EP2299987B1 (en) 2008-06-06 2018-02-21 Boehringer Ingelheim International GmbH Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
JP6209446B2 (ja) * 2010-06-02 2017-10-04 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CA2883807A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US20150209360A1 (en) * 2014-01-30 2015-07-30 Orbz, Llc Oral caffeine delivery composition
CN106031716B (zh) * 2015-03-13 2022-04-15 江苏豪森药业集团有限公司 含有吲哚满酮衍生物混悬液的药物制剂及其制备方法
AU2016276170B2 (en) 2015-06-06 2021-08-05 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
CN107019697A (zh) * 2016-02-02 2017-08-08 瑞阳(苏州)生物科技有限公司 预防或治疗纤维化疾病的药物组合物及其应用
CN119656170A (zh) 2016-06-02 2025-03-21 拨康视云生物医药科技(广州)有限公司 使用尼达尼布来治疗具有异常新生血管形成的眼病的组合物和方法
WO2018080795A1 (en) * 2016-10-25 2018-05-03 Glykon Technologies Group, Llc Hydroxycitric acid compounds and capsule liquid delivery
CN108066343A (zh) * 2016-11-08 2018-05-25 瑞阳(苏州)生物科技有限公司 一种预防或治疗肾纤维化疾病的药物
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
JP2020512364A (ja) 2017-03-28 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 筋ジストロフィーの処置方法において使用するためのニンテダニブ
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
EP4603094A2 (en) 2017-10-23 2025-08-20 Boehringer Ingelheim International GmbH New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
WO2019106692A1 (en) * 2017-11-29 2019-06-06 Sun Pharmaceutical Industries Limited Oral suspension of nintedanib esylate
PT3761980T (pt) 2018-03-07 2024-02-29 Pliant Therapeutics Inc Compostos de aminoácidos e métodos de utilização
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN113301884A (zh) * 2018-09-13 2021-08-24 夫特弗制药私人有限公司 非水性化疗口服悬浮液
CA3116298A1 (en) * 2018-10-15 2020-04-23 Cipla Limited Pharmaceutical formulation
CN112386580B (zh) * 2019-08-13 2022-07-08 齐鲁制药有限公司 具有改善的溶出度和稳定性的尼达尼布药物制剂、制备方法及其应用
AU2020397207A1 (en) 2019-12-04 2022-07-21 Idorsia Pharmaceuticals Ltd Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
US20230135671A1 (en) 2020-04-01 2023-05-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
AU2022366992A1 (en) * 2021-10-14 2024-05-16 Pliant Therapeutics, Inc. Integrin inhibitors and uses thereof in combination with other agents
CN114404382B (zh) * 2022-01-24 2023-05-12 南京康川济医药科技有限公司 乙磺酸尼达尼布软胶囊及其制备方法
US20250161250A1 (en) 2022-02-28 2025-05-22 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
JP2025525881A (ja) 2022-08-16 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼内使用するためのニンテダニブの医薬製剤
WO2025254255A1 (ko) 2024-06-05 2025-12-11 영진약품 주식회사 닌테다닙 또는 이의 약학적으로 허용가능한 염을 포함하는 개선된 용출률을 갖는 신규한 정제 및 이의 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007054551A1 (en) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
EP0169398B1 (de) 1984-07-24 1990-08-29 R.P. Scherer GmbH Oxytetracyclin-HC1-Weichgelatinekapseln und Verfahren zu ihrer Herstellung
GB9313329D0 (en) * 1993-06-28 1993-08-11 Scherer Ltd R P Softgel capsule shell compositions
DE19603402A1 (de) 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
PL366453A1 (en) * 2001-05-01 2005-02-07 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20060293260A1 (en) * 2005-05-24 2006-12-28 Wyeth Useful high load concentrate compositions for control of ecto-and endo-parasites
EP2985025B1 (en) * 2008-06-06 2018-01-17 Boehringer Ingelheim International Gmbh Pharmaceutical combination
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
EP2299987B1 (en) 2008-06-06 2018-02-21 Boehringer Ingelheim International GmbH Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
JP2012515184A (ja) * 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大腸がんの治療方法
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
JP2012526766A (ja) 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍性及び線維性疾患の処置における新規な併用療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007054551A1 (en) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors

Also Published As

Publication number Publication date
UA104590C2 (ru) 2014-02-25
NO2299987T3 (enExample) 2018-07-21
BRPI0913434A2 (pt) 2015-12-01
US9907756B2 (en) 2018-03-06
LT2299987T (lt) 2018-05-25
CL2010001279A1 (es) 2011-05-13
CN105193720B (zh) 2018-07-31
JP5661031B2 (ja) 2015-01-28
US20160324791A1 (en) 2016-11-10
US20160022672A1 (en) 2016-01-28
CO6280467A2 (es) 2011-05-20
ECSP10010660A (es) 2011-02-28
TW201002691A (en) 2010-01-16
CN105193720A (zh) 2015-12-30
EA201001856A1 (ru) 2011-06-30
MX359229B (es) 2018-09-20
CN102056598B (zh) 2017-09-19
US20110301177A1 (en) 2011-12-08
JP5905542B2 (ja) 2016-04-20
HRP20180709T1 (hr) 2018-06-15
IL208954A0 (en) 2011-01-31
UY31879A (es) 2010-01-29
AU2009254548A1 (en) 2009-12-10
ZA201007636B (en) 2011-08-31
BRPI0913434B1 (pt) 2020-10-13
WO2009147212A1 (en) 2009-12-10
ES2669469T3 (es) 2018-05-25
EA029996B1 (ru) 2018-06-29
MY158930A (en) 2016-11-30
RS57142B1 (sr) 2018-07-31
NZ603162A (en) 2014-05-30
CA2726267A1 (en) 2009-12-10
PL2299987T3 (pl) 2018-08-31
US20140004187A1 (en) 2014-01-02
PT2299987T (pt) 2018-05-21
JP2011522812A (ja) 2011-08-04
CA2726267C (en) 2017-10-31
HUE039187T2 (hu) 2018-12-28
EP2299987B1 (en) 2018-02-21
IL208954A (en) 2017-11-30
MX2010013203A (es) 2011-02-25
KR20110017872A (ko) 2011-02-22
MA32385B1 (fr) 2011-06-01
AR072059A1 (es) 2010-08-04
EP2299987A1 (en) 2011-03-30
AU2009254548B2 (en) 2015-10-01
SI2299987T1 (en) 2018-06-29
JP2014208712A (ja) 2014-11-06
BRPI0913434B8 (pt) 2021-05-25
CN102056598A (zh) 2011-05-11
PE20100254A1 (es) 2010-04-21
DK2299987T3 (en) 2018-05-22
KR20170020557A (ko) 2017-02-22
CY1120533T1 (el) 2019-07-10

Similar Documents

Publication Publication Date Title
KR101725469B1 (ko) 인돌리논 유도체의 현탁 제형을 포함하는 캡슐 약제학적 투여 형태
JP5583119B2 (ja) インドリノン誘導体の即時放出のための医薬投薬形態
US10105323B2 (en) Pharmaceutical dosage form for immediate release of an indolinone derivative
AU2015227503B2 (en) Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
HK1152477A (en) Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
AU2015210331A1 (en) Pharmaceutical dosage form for immediate release of an indolinone derivative
HK1152641A (en) Pharmaceutical dosage form for immediate release of an indolinone derivative

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101203

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140602

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160119

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161020

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160119

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20170118

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20161020

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20170306

Appeal identifier: 2017101000266

Request date: 20170118

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170216

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20170118

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20170118

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20160719

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20140602

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20170306

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20170221

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170405

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170406

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200327

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210326

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220325

Start annual number: 6

End annual number: 6

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20240417

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20170405

Comment text: Registration of Establishment

Request date: 20240417

Appeal identifier: 2024100001127

Appeal kind category: Confirmation of the scope of right_defensive

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20241117

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20170405

Comment text: Registration of Establishment

Request date: 20241117

Appeal identifier: 2024100003340

Appeal kind category: Confirmation of the scope of right_defensive